Inactive Instrument

Dimension Therapeutics Inc Stock

Equities

Duration

Period

Style

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”	17-10-02	GL
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”	17-09-19	GL
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx	17-09-18	GL
Dimension Therapeutics : OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors	17-09-05	PR
Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information	17-08-31	BU

Managers	Title	Age	Since
Thomas Kassberg PSD	President	63	17-11-06
Stephanie Haller CTO	Chief Tech/Sci/R&D Officer	-	14-10-31
Karah Parschauer BRD	Director/Board Member	46	17-11-06

Members of the board	Title	Age	Since
Karah Parschauer BRD	Director/Board Member	46	17-11-06

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.43%	102B
REGENERON PHARMACEUTICALS, INC.	+2.15%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.56%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.16%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.54%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.20%	11.06B